Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

2.

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.

Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Da Mota DF, Gilhodes J, Filleron T, Siegfried A, Evrard S, Kowalski-Chauvel A, Moyal EC, Toulas C, Lemarié A.

Mol Cancer Res. 2019 Feb;17(2):384-397. doi: 10.1158/1541-7786.MCR-18-0386. Epub 2018 Sep 28.

PMID:
30266751
3.

Integrins and p53 pathways in glioblastoma resistance to temozolomide.

Martin S, Janouskova H, Dontenwill M.

Front Oncol. 2012 Oct 31;2:157. doi: 10.3389/fonc.2012.00157. eCollection 2012.

4.

Invasion as target for therapy of glioblastoma multiforme.

Vehlow A, Cordes N.

Biochim Biophys Acta. 2013 Dec;1836(2):236-44. doi: 10.1016/j.bbcan.2013.07.001. Epub 2013 Jul 25. Review.

PMID:
23891970
5.

Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.

Scaringi C, Minniti G, Caporello P, Enrici RM.

Anticancer Res. 2012 Oct;32(10):4213-23. Review.

PMID:
23060541
6.

[The stem cell niche in glioblastoma: from fundamental aspects to targeted therapies].

Turpin A, Sharif A, Stoven L, Blond S, Maurage CA, Le Rhun É.

Bull Cancer. 2015 Jan;102(1):24-33. doi: 10.1016/j.bulcan.2014.07.001. Epub 2015 Jan 6. Review. French.

PMID:
25609493
7.

Individualized targeted therapy for glioblastoma: fact or fiction?

Weller M, Stupp R, Hegi M, Wick W.

Cancer J. 2012 Jan-Feb;18(1):40-4. doi: 10.1097/PPO.0b013e318243f6c9. Review.

PMID:
22290256
8.

Combination therapy to checkmate Glioblastoma: clinical challenges and advances.

Ghosh D, Nandi S, Bhattacharjee S.

Clin Transl Med. 2018 Oct 16;7(1):33. doi: 10.1186/s40169-018-0211-8. Review.

9.

Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells.

Podergajs N, Motaln H, Rajčević U, Verbovšek U, Koršič M, Obad N, Espedal H, Vittori M, Herold-Mende C, Miletic H, Bjerkvig R, Turnšek TL.

Oncotarget. 2016 Jan 5;7(1):593-609. doi: 10.18632/oncotarget.5477.

10.

Glioblastoma stem cells.

Tabatabai G, Weller M.

Cell Tissue Res. 2011 Mar;343(3):459-65. doi: 10.1007/s00441-010-1123-0. Epub 2011 Jan 21. Review.

PMID:
21253762
11.

A novel treatment for glioblastoma: integrin inhibition.

Chamberlain MC, Cloughsey T, Reardon DA, Wen PY.

Expert Rev Neurother. 2012 Apr;12(4):421-35. doi: 10.1586/ern.11.188. Review.

PMID:
22449214
12.

Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells.

Oh MC, Kim JM, Safaee M, Kaur G, Sun MZ, Kaur R, Celli A, Mauro TM, Parsa AT.

PLoS One. 2012;7(10):e47846. doi: 10.1371/journal.pone.0047846. Epub 2012 Oct 23.

13.

CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.

Würth R, Bajetto A, Harrison JK, Barbieri F, Florio T.

Front Cell Neurosci. 2014 May 28;8:144. doi: 10.3389/fncel.2014.00144. eCollection 2014. Review.

14.

Molecular advances of brain tumors in radiation oncology.

Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A.

Semin Radiat Oncol. 2009 Jul;19(3):171-8. doi: 10.1016/j.semradonc.2009.02.005. Review.

PMID:
19464632
15.

A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.

Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN.

Cancer Res. 2016 Apr 15;76(8):2465-77. doi: 10.1158/0008-5472.CAN-15-2402. Epub 2016 Feb 19.

16.

Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets.

Fève M, Saliou JM, Zeniou M, Lennon S, Carapito C, Dong J, Van Dorsselaer A, Junier MP, Chneiweiss H, Cianférani S, Haiech J, Kilhoffer MC.

PLoS One. 2014 Mar 24;9(3):e91519. doi: 10.1371/journal.pone.0091519. eCollection 2014.

17.

Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma.

Kalkan R.

Clin Med Insights Oncol. 2015 Nov 16;9:95-103. doi: 10.4137/CMO.S30271. eCollection 2015. Review.

18.

Novel strategies for the treatment of chondrosarcomas: targeting integrins.

Chen JC, Fong YC, Tang CH.

Biomed Res Int. 2013;2013:396839. doi: 10.1155/2013/396839. Epub 2013 Dec 30. Review.

19.

[Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment].

Figarella-Branger D, Colin C, Tchoghandjian A, Baeza N, Bouvier C.

Neurochirurgie. 2010 Dec;56(6):441-8. doi: 10.1016/j.neuchi.2010.07.010. Epub 2010 Sep 16. Review. French.

PMID:
20817192
20.

Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T, Daga A.

Cell Cycle. 2013 Feb 1;12(3):491-500. doi: 10.4161/cc.23372. Epub 2013 Jan 16.

Supplemental Content

Support Center